Bone Biologics Corp, headquartered in Burlington, Massachusetts with 2 employees, went public in 2015 and specializes in bone regeneration for spinal fusion using NELL-1/DBM. This biotech company develops a platform technology focusing on bone and cartilage regeneration across various medical applications.
Bone Biologics Corp (BBLG) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Bone Biologics Corp's actual EPS was -$1.31, beating the estimate of -$7.75 per share, resulting in a 83.10% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
